thanks, to a today. joining for to be pleasure here and us Tracy, provide Thanks, everyone, update. an It's
some with despite We COVID-XX million, delivered revenue related representing third performance of our are year, quarter headwinds. pleased $XX.X the over growth the in as prior we of XX%
the nCounter access of tests the advancing update, and system. of growing the pursue have with market physicians strategy. CLIA key KOL we for the inclusion guideline process HalioDx, also process menu last develop U.S. onto evidence the test future LDTs since August, via and significantly all transfer our are their instrument. to nCounter, in our patients provide own will our manufacture of in reimbursement kits to our our adoption. labs. one We we executed some the around and the of securing on world to We were In This development, our to they as our completed for considering publications, tests, developed acquisition the Prior a transitioning of which of milestones
are workflow. growing into leverage up our in answer they unmet field. to not the physician's in deep fitting but rapidly the needs expertise clinical whole designed tests while And scientific also Our only very genomics, from immuno-oncology, transcriptome now our ground a expertise specific
With indication. now addition by address top of cancers we of HalioDx, X the XX the in the U.S.
out for whom over can for menu successfully expanding it clinical world our Our by, partnerships menu outcomes assist treatment tests and providing the cancer of detect provide to the therapies their development diagnostic decisions, clarity, physicians physicians and at helping by and journey improve example, with data will unnecessary treated. To ruling we the patients of biopharma treatment further genomic when all helping companies diagnostics. step early surgeries, of patients, of tests is our with every to to extensive our services bolstered or be of in companion assist with
results. Turning to the quarterly now
strategic drivers ongoing traction our commercial Beginning continued pipeline in genomic As to expansion. and always, advancement of further the classifier global Prostate strong fueled growth, of the team in commercial the evidence progress I'll market, growth, our Decipher context by expansion. gain discuss development, with sales
million of in more making for and the coverage people as Decipher than covered to community the the covered for nationally additional Prostate, expanded and urologist impacted recall business our settings many by reps. opposed that test an hospitals, XXX a to accessible benefit more settings bringing COVID-XX been participants, less is and X our number million prostate community sales customers practice to We cancer patients plan general have in total in will You lives because our U.S. of
a treatment with NCCN, Blues based specifically contract September, recommend signed national large its which upon or Network, the published Cancer and also or guidelines, payer. a a decisions post-radical National XXXX plan score. new In the Comprehensive government We Decipher RP prostatectomy, patient's
prostate recommendation, to further only test which with genomic Ours reimbursement. will is help believe of level this we and cancer drive the adoption
Our variant. be our our than COVID, performed access, Sequencing Klopper case sequentially, in the count further slightly in particularly establishing vacations, high. and both on in welcome original more Endocrinology. samples were a diagnosis. and challenges where he to hospital of prior come staffing those Afirma the we Classifier, from Dr. care limiting summer care hospital to investigator volume Approximately higher utility new as Klopper cancer. the COVID-XX GSC by new Afirma typical of role ongoing thyroid standard development Afirma of Genomic clinical for continues year, cancer key procedures a or impacted setting, have as also in market been an biopsy of although guiding tended test the have rates and work our GSC, Afirma delta over to was the and Medical pleased thyroid Dr. with will revenue from seasonality areas and play our shortages Joshua hospitalizations to Director sales experienced procedures We test, were study XX% in which be increased standard for and rep down
reduction the engagement prior educational our access, continue to marketing quarters. limited saw other we Percepta events, and targets in Despite continued pulmonology and GSC the educate tests. stems to by by to Envisia of to products peer-to-peer number communications. KOL-led our customers both digital impacted our leveraging awareness tools the used build and be for procedure digital with samples pulmonology ongoing online as collect from of Our we in business This COVID bronchoscopies,
gained report competitive test in business molecular where ability advantages. subtype laboratories and key Europe to cancer to breast information enable Prosigna locally momentum our Our us the gives perform
test's abstracts reinforced we in The for cancer help our studies Our At adoption the test major next We to of our our will and X patients that also unveiled October, our at X annual our and and driver meeting Swab, growth conferences, for assess with development. strong evidence nodule the reimbursement data validation findings evidence and across which had showed nodules. further risk pulmonology tests. physicians ability expanded clinical strategic urologic boosted products Nasal facilitate clinical library patients clinical further CHEST lung with is delivers medical in cancer, and endocrinology stages cancer cancers. different other performance published we sizes have which help for lung across Percepta who already believe
Society test cancer the Accurate, quickly to and IPF that impact treatment begin low diagnosis slow for for when they can that that for IPF. frequently of Importantly, also treatments Conversely, American prostate which guided were lung cancer, immunosuppressive cancers. patients shared for to its more to the showed physician can disease, of risk new patients patients therapy. the findings because results timely harmful as data for disease, they if and with high were it nasal miss procedures fibrosis, will identifies at studies to with Oncology, was meaning that ASTRO, it it Further, meaning decision can the Also that was meeting agents, study disease. their the confident are at is its swab October. few antifibrotics initiate the shared high, specificity our treat showed from XX%, diagnose X help The used that IPF actually or sensitivity that diseases, and test are have their in for diagnostic the progression Envisia risk data more likely XX%, annual important more IPF, interstitial cancer, in showed be very very many interstitial important patients high, when enable also further decision test pulmonary who likely can researchers as lung Data of for CHEST them that needed. of identifies idiopathic IPF. including patients to diagnosis be to when use did increased can Radiation lung meeting, or ensure
overall first Decipher up. randomized case, a In of genomic to cancer our any Results the test years. median with high prostate the clinically of therapy. mortality of this that Prostate prostate patients first patients The with a can The scores was may that care require suggest which findings identify distant standard are use with and study, the test patients use Prostate in Decipher help cancer. validate independently associated prostate follow who in test long-term metastases, of treatment beyond demonstrated survival test, of risk specific cohort cancer prospective XX examined intensification
RP cancer progression Additionally, trial randomized, men and following findings Phase the suggest treatment can at a Prostate test surgery. Decipher timing guide intensity ASTRO for prostate from experiencing III of that presented multicenter,
identified accurately respond in Urology These decisions the For prior manage our for chemotherapy that ultimately most their with has showing to many likely the tool no treatment bladder Decipher overuse benefit types, patients bladder cancer to were were biology. now, help optimize neoadjuvant resulting Until new based patients whose reliable tumor physicians there suggest data subtype their helps planning little of Journal for these that physicians in cancer published the cystectomy. way the treatment that bladder test radical to tumors with test bladder cancer, to findings test, patients. been for patients could distinguish physicians of upon chemotherapy with for
GSC for testing. needle These among the Additionally, whose in clinical resulted that no molecular surgeries results aspiration use were GSC findings of results nodule Society. patients who of fine fewer the XX% a to showed the study compared Afirma had Afirma Endocrine the utility long-term published patients thyroid Journal were in indeterminate of
compared cancer was deemed twice as cancer have GSC Additionally, had testing. were to when likely molecular for patients by no to those who suspicious nearly performed, Afirma surgery the
is driver. advancement, growth which third Turning pipeline to our strategic
our to diagnostic Swab reliably early nodules ability annual the eligible lack million cancer next with We and key significant to increasingly physicians steps number which and likely tools X.X directed unnecessary accurate if patients We have assessment have to and procedures, currently cancer test can Americans is be therefore becomes incidentally, million Nasal need October. healthcare test this of further for to XX delighted patients believe screening physicians determine benign in and We needed. should lung the which workup risk because today launch cancer diagnostic recently determine found lung nodules for objective and achieved likely are for and important for clinical were With lung lung milestones. patients, treatment avoid a Percepta the system.
that believe when early cancers Percepta more noninvasive can we the Swab, will Nasal treated. they detected be be lung successfully With
the genomic months Atlas, post-launch to are in as now profiling Percepta lung of to to patient serving We to diagnosis evidence study. portfolio from test early an to clinical X in available engage our treatment. the that limited would patients test reimbursement, we up launch working round of the secure in we plan cancer Genomic Percepta utility receive progressing. help anticipate lung early sites expect Nasal assemble our We products utility on a XX Works number clinical The sites to is XXXX XX for lab making Swab detection cancer, with still X our confirmed CLIA test to out reimbursement. to and will and test initial our the
launch Another Decipher our test. was key product bladder
offering that urology business. test without has Decipher a the prostate prostate the which The we of test, to growing XX,XXX with year serve and team begun to of help treatment patients to could sales will maximize our our potential up our steady same we disrupting in the be that Our the launch long-term this physicians customers, measured ensure test.
welcome Vincent expansion. completed General operations; Danan Global I've and As Debono and in of of Fabienne EVP Manager to executive as Corinne Regulatory on General acquisition marking and of biopharma leaders and I as company's Hermitte step its Stephane as we SVP a and key as our BU; global to to namely HalioDx EU August mentioned X, Quality Manager and Fert, Immunoscore of plan strategic talented been my team International delighted of team, new Immuno-Oncology our Veracyte X Diagnostic Affairs. earlier, SVP for Operations; SVP the our and
additional parallel, in IVD can IVD will transition, the product analysis to including collaborating combined estimate take give our their Nasal This patients of months, the over Prostate manufacturing Percepta tests, make which control Our in we test to is plan us XX Swab and team the In Envisia, end-to-end already business. port from move so that them Decipher facility France. on system physicians markets. our global will to we available to nCounter our we and NanoString
Immunogram area and of tumor scientific leverage South of development multimodal We have these be clinicians The made to range experienced and site, immuno-oncology, for you insights course. help San with emerging to exciting projects, the look Diego, predict plans microenvironment. the a forward our the inform in progress due decisions an between The impressive helping products the to understand on the degree of XXX teams biopharma to our will which into great and updating the and tumor I patient potential offering into acquisition analysis treatment for expands partners collaboration finalizing immunotherapy gives risk expertise to services timing Francisco, response biomarker our HalioDx in in also partners them R&D San Marseille, care that platform biopharma further recurrence. novel from of patient a
to and integration businesses. In on a positioned which we the delivered well Additionally, us tests giving brought responding to further how strong and cancer from physicians measurement leaders summary, had The solid extremely the to far. in physician both so their quarter actionable test a of ensure and tirelessly we while revenue I'd workstream treatment decision to making respective has teams system and an goals Immunoscore acquisition thank that cancer. immune patient's like is strong maintaining worked test. adoption individual reimbursement. the integration HalioDx focus who colon our our is intended have year-over-year and a accomplished Bonnie growth gone by their This and clear we Veracyte has guide for
We the Rebecca acquisition over successful significant achieve growth in turn now progress global for HalioDx the the through call detailed of to of our also transforming overview I'll the to and a of give results. products company new our key made vision. to long-term strategic through launches
